← All trials
NCT06893016
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 15, 2025
- Primary completion
- Jun 15, 2026
- Completion date
- Sep 15, 2026
- First posted
- Mar 25, 2025
- Last posted
- Jul 17, 2025
- Enrollment
- 640
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Guangdong Raynovent Biotech Co., LtdLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.